MS Rendell, L Jovanovic - Metabolism, 2006 - Elsevier In healthy individuals, blood glucose levels in the fasting state are maintained
by the continuous basal-level insulin secretion. After a meal, the rise in
postprandial glucose (PPG) is controlled by the rapid pancreatic release of ... Cited by 29 - Related articles - All 12 versions
- ►diabetesjournals.org K Rave, O Klein, AD Frick, RHA Becker - Diabetes Care, 2006 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In a single-dose, randomized, four-way complete
cross-over study, subjects received standardized, 15-min meals, covered by
subcutaneous injections of either insulin glulisine (immediately premeal or ... Cited by 28 - Related articles - BL Direct - All 6 versions
SK Garg, SL Ellis, H Ulrich - eop, 2005 - informahealthcare.com Insulin glulisine (Apidra®, Sanofi-Aventis), a new and recently approved rapid-
acting insulin analogue, mimics the pharmacokinetic and pharmacodynamic profiles
of physiological human insulin, but has a rapid onset, peak effect at 1 h, ... Cited by 24 - Related articles - BL Direct - All 4 versions
RHA Becker - Diabetes Technology & Therapeutics, 2007 - liebertonline.com 29 B Glu-human insulin) is a new fast-acting analog that provides absorption and
onset of action more rapidly with a shorter duration of action compared with
regular human insulin, and thus better resembles physiologic mealtime ... Cited by 23 - Related articles - BL Direct - All 3 versions
G Rayman, V Profozic, M Middle - Diabetes research and clinical practice, 2007 - Elsevier Mean baseline characteristics were similar between groups. There were no
differences in baseline to endpoint HbA 1c reductions (glulisine: −0.32%; RHI:
−0.35%; p = 0.5726), and the non-inferiority of glulisine versus RHI was ... Cited by 18 - Related articles - All 8 versions
M Thevis, A Thomas, W Schanzer - Mass Spectrometry Reviews, 2008 - assets0.pubget.com Insulins' anabolic and anti-catabolic properties have sup- posedly led to its
misuse in sport. Hence, doping control assays were developed to allow the
unequivocal identification of synthetic insulin analogs and metabolic ... Cited by 13 - Related articles - View as HTML - BL Direct - All 3 versions
- ►fetalneonatal.com T Danne, K Lange, O Kordonouri - Archives of Disease in Childhood, 2007 - adc.bmjjournals.com.p.angrylapdog.com Both type 1 and type 2 diabetes can occur in children and adolescents. Of the
230 million people affected by diabetes worldwide, 4.9 million have type 1
diabetes. Type 1 diabetes is the most common chronic disease in children in ... Cited by 12 - Related articles - BL Direct - All 5 versions
SL Cox - Drugs of Today, 2005 - journals.prous.com In patients with diabetes, the benefit of conventional insulin therapy can be
limited due to difficulty in achieving tight glycemic control, which is critical
to reducing the risk of long-term diabetes-related complications. The ... Cited by 10 - Related articles - All 5 versions
M Thevis, M Kohler, W Schänzer - Drug discovery today, 2008 - Elsevier The issue of doping in sport is multifaceted. New drugs not only with anabolic
properties such as selective androgen receptor modulators, synthetic insulins,
blood doping with erythropoietins or homologous and autologous blood ... Cited by 9 - Related articles - All 4 versions
AD Kamal, SC Bain - Expert Opin. Drug Saf., 2007 - informahealthcare.com Glulisine insulin is the latest addition to the class of rapid-acting insulin
analogues. It is important that it is comparable in safety not only to human
regular insulin, but also to the well established analogue insulins, aspart ... Cited by 8 - Related articles - BL Direct - All 6 versions
